Brokerages Set Mural Oncology PLC (NASDAQ:MURA) PT at $12.00

Mural Oncology PLC (NASDAQ:MURA) has received a consensus rating of “Hold” from the five ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $12.00.

MURA has been the topic of several recent analyst reports. Wall Street Zen lowered Mural Oncology from a “hold” rating to a “strong sell” rating in a report on Sunday, August 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Mural Oncology in a report on Saturday, September 27th.

Mural Oncology Price Performance

NASDAQ:MURA opened at $2.08 on Friday. The firm has a market capitalization of $36.05 million, a PE ratio of -0.24 and a beta of 2.93. The business’s fifty day moving average price is $2.02 and its 200 day moving average price is $2.23. Mural Oncology has a 12 month low of $0.95 and a 12 month high of $4.74.

Mural Oncology (NASDAQ:MURA) last posted its earnings results on Monday, August 4th. The company reported ($1.77) EPS for the quarter, missing the consensus estimate of ($1.13) by ($0.64). As a group, equities analysts anticipate that Mural Oncology will post -7.54 EPS for the current year.

Hedge Funds Weigh In On Mural Oncology

Several hedge funds have recently made changes to their positions in the company. Armistice Capital LLC grew its holdings in shares of Mural Oncology by 1.3% during the first quarter. Armistice Capital LLC now owns 1,722,000 shares of the company’s stock worth $2,170,000 after purchasing an additional 22,000 shares during the last quarter. Soleus Capital Management L.P. purchased a new position in shares of Mural Oncology during the second quarter worth about $3,270,000. Orbimed Advisors LLC purchased a new position in shares of Mural Oncology during the second quarter worth about $1,454,000. LMR Partners LLP purchased a new position in shares of Mural Oncology during the second quarter worth about $1,276,000. Finally, Diametric Capital LP purchased a new position in shares of Mural Oncology during the second quarter worth about $864,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.